- Home
- EQ vs GYGY Comparison
EQ vs GYGY Comparison
Compare EQ & GYGY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EQ | GYGY |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.4M | 130.6M |
| IPO Year | 2018 | 2026 |
Fundamental Metrics
Financial Performance| Metric | EQ | GYGY |
|---|---|---|
| Price | $2.33 | $2.17 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 492.6K | 193.2K |
| Earning Date | 05-25-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,095,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.76 | $2.03 |
| 52 Week High | $3.54 | $11.81 |
Technical Indicators
Market Signals| Indicator | EQ | GYGY |
|---|---|---|
| Relative Strength Index (RSI) | 45.79 | N/A |
| Support Level | $1.68 | $2.03 |
| Resistance Level | $2.61 | N/A |
| Average True Range (ATR) | 0.19 | 1.26 |
| MACD | 0.00 | -0.46 |
| Stochastic Oscillator | 59.62 | 1.43 |
Price Performance
Historical ComparisonAbout EQ Equillium Inc.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.